Copaxone, Glatopa
Evidence Grade A — Regulatory approved. 2150 published studies. 119 registered clinical trials.
Loading...
Glatiramer acetate (sold as Copaxone and the generic Glatopa) is an injectable treatment for relapsing forms of multiple sclerosis (MS). Rather than being a single molecule, it is a mixture of protein fragments designed to resemble a component of the nerve insulation (myelin) that the immune system mistakenly attacks in MS. It has been a mainstay of MS treatment since 1996, though newer therapies have increasingly taken its place.
2,150 published studies: 1614 human, 151 animal, 109 in-vitro, 587 reviews
Glatiramer acetate is marketed as Copaxone (approved December 1996) and the generic Glatopa (approved 2015). Available as 20 mg daily or 40 mg three-times-weekly subcutaneous injections. It is indicated for relapsing forms of MS including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
Clinical trials showed glatiramer acetate reduces relapse rates by approximately 29–34%. Long-term follow-up data extending to 15 years suggest sustained lower disability scores. Its safety profile is well-established — injection-site reactions are the main side effect, with an occasional transient post-injection systemic reaction. However, glatiramer acetate has been increasingly displaced by higher-efficacy therapies (including oral agents and monoclonal antibodies) that have become available for MS.
In MS, the immune system mistakenly attacks myelin — the insulating coating around nerve fibres. Glatiramer acetate resembles myelin basic protein closely enough that it redirects the immune response. It competes with myelin fragments for binding on immune cells, and crucially, it shifts the T-cells that recognise it from aggressive (Th1) to protective (Th2/regulatory) types. These re-educated immune cells then travel to the brain and spinal cord, where they encounter similar myelin proteins and release anti-inflammatory signals instead of attacking.
Clinical trials showed glatiramer acetate reduces MS relapse rates by approximately 29-34%, with long-term follow-up data extending to 15 years suggesting sustained benefits for disability. Its safety profile is well-established over more than 25 years — injection-site reactions are the main side effect, with no cases of the serious brain infection (PML) that is associated with some more potent MS treatments. However, glatiramer acetate has been increasingly displaced by higher-efficacy therapies including oral drugs (like fingolimod and dimethyl fumarate) and monoclonal antibodies (like ocrelizumab and natalizumab) that offer stronger disease control. It is now primarily positioned as a first-line treatment for milder forms of MS, where its well-known safety profile is valued over maximum disease suppression.
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
Ultra-high-field Brain MRI in Multiple Sclerosis
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 3
FDA SUPPL 2
FDA SUPPL 5
FDA SUPPL 6
FDA SUPPL 8
FDA SUPPL 10
FDA SUPPL 11
FDA SUPPL 12
FDA SUPPL 14
FDA SUPPL 13
FDA SUPPL 16
FDA SUPPL 17
FDA SUPPL 9
FDA SUPPL 4
FDA SUPPL 7
FDA SUPPL 18
FDA SUPPL 19
FDA SUPPL 20
FDA SUPPL 22
FDA SUPPL 15
FDA SUPPL 23
FDA SUPPL 24
FDA SUPPL 25
FDA SUPPL 26
FDA SUPPL 57
FDA SUPPL 79
FDA SUPPL 87
FDA SUPPL 85
FDA SUPPL 83
FDA SUPPL 91
FDA SUPPL 89
FDA SUPPL 92
FDA ORIG 1
FDA SUPPL 94
FDA SUPPL 96
FDA SUPPL 95
FDA SUPPL 93
FDA SUPPL 98
FDA SUPPL 99
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 102
FDA ORIG 1
FDA SUPPL 104
FDA SUPPL 106
FDA SUPPL 107
FDA SUPPL 109
FDA SUPPL 110
FDA SUPPL 5
FDA SUPPL 1
FDA SUPPL 20
FDA SUPPL 8
FDA SUPPL 17
FDA SUPPL 21
FDA SUPPL 18
FDA SUPPL 22
FDA SUPPL 20
FDA SUPPL 8
FDA SUPPL 113
FDA SUPPL 114
FDA SUPPL 9
FDA SUPPL 16
FDA SUPPL 7
FDA SUPPL 12
FDA SUPPL 3
FDA SUPPL 17
FDA SUPPL 8
FDA SUPPL 17
FDA SUPPL 8
FDA SUPPL 4
FDA SUPPL 11
FDA SUPPL 9
FDA SUPPL 16
FDA SUPPL 7
FDA SUPPL 24
FDA SUPPL 25
FDA SUPPL 26
FDA SUPPL 25
FDA SUPPL 115
FDA SUPPL 27
FDA SUPPL 28
FDA SUPPL 116
FDA SUPPL 20
FDA SUPPL 19
FDA SUPPL 19
FDA SUPPL 20
FDA SUPPL 28
FDA SUPPL 29
Health Canada Market Authorisation
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 118
FDA SUPPL 119
FDA SUPPL 31
FDA SUPPL 32
FDA ORIG 1
FDA SUPPL 2
FDA SUPPL 2
FDA ORIG 1
FDA SUPPL 32
FDA SUPPL 33
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
